Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer
Publication Date
2020
Journal Title
Future Oncol
Volume Number
16
Issue Number
1
Pages
4289 - 4301
Document Type
Article
Status
Faculty
Facility
School of Medicine
Primary Department
Hematology/Medical Oncology
PMID
DOI
10.2217/fon-2019-0653
This document is currently not available here.
COinS
Comments
Hofstra Northwell School of Medicine and Northwell Health currently do not subscribe to this title. If you are an affiliate and would like to access the full text please request it via interlibrary loan via Hofstra Northwell School of Medicine ILL (faculty and students only) or Northwell Health ILL